Dan Whitfield for Arkansas US Inactive
DANWHITCONGRESS
⚠ Creative removed by Meta
This ad's image was taken down for violating Meta's ad standards; the copy below is preserved from the Ad Library.
This ad's image was taken down for violating Meta's ad standards; the copy below is preserved from the Ad Library.
Ad copy
When a vaccine is completed the pharmaceutical companies should sell the COVID-19 vaccine AT COST. This is not the time to profiteer or capitalize on an epidemic. Arkansans should receive paid sick leave for the time they are away from work due to this state of emergency event in order to prevent spread. We should also consider putting a one month hold on utilities and mortgages/rent costs. www.ReplaceTomCotton.com
↗ View in Meta Ad Library (the live creative — image/video/layout)
Performance proxies
| Overall score | 35.1/100 |
| Spend / Reach / Long. / Eff. | 11.9 · 59.2 · 0.6 · 68.8 |
| Spend range | USD 100–199 |
| Impressions | 15,000 – 19,999 |
| CPM (≈ $/1k impr) | USD 8.54 |
| Est. audience size | — |
| Days live | 3 (2020-03-13 → 2020-03-16) |
| Created | 2020-03-13 |
| Creative variants | 1 body · 0 headline |
| Platforms | |
| Languages | en |
| Candidate | AR — Dan Whitfield |
| Surfaced by | “senate:Dan Whitfield” |
🧠 AI analysis
| Issue | healthcare |
| Framing | issue advocacy |
| Message type | persuasion |
| Emotional appeal | urgency |
| Production tier | diy amateur |
| Who pictured | candidate |
| Symbols | none |
| Call to action | none |
| Standout element | Facebook content-removed notice replacing the actual ad creative |
| Tactic | The ad is effectively invisible due to a disclaimer violation, undermining its COVID-19 relief message entirely; the removal notice is the only content visible. |
Where it ran (delivery by region)
| Arkansas | 100.0% |
Who saw it (delivery)
| 45-54 · male | 5.9% |
| 18-24 · female | 2.2% |
| 45-54 · unknown | 0.1% |
| 55-64 · unknown | 0.2% |
| 65+ · unknown | 0.2% |
| 25-34 · unknown | 0.3% |
| 35-44 · unknown | 0.2% |
| 18-24 · male | 1.2% |
| 25-34 · female | 8.0% |
| 65+ · female | 16.7% |
| 35-44 · female | 12.1% |
| 45-54 · female | 12.7% |
| 25-34 · male | 4.1% |
| 65+ · male | 6.7% |
| 55-64 · male | 6.8% |
| 35-44 · male | 5.1% |
| 55-64 · female | 17.4% |
| 18-24 · unknown | 0.1% |
